Investigação in vitro da atividade antifúngica de novos compostos derivados de Pirazois

Abstract

Various treatments have been suggested for the treatment of denture stomatitis but problems such as toxicity and antibiotic resistance can be observed. This study evaluated the in vitro antifungal activity, anti-enzymatic and cytotoxic new compounds pirazolínicos. Were used strains of Candida albicans (33), C. parapsilosis (2), C famata (2), C glabrata (2) and C lipolytica (2). The antifungal activity was evaluated by minimum inhibitory concentration (MIC) and Minimum Fungicide (MFC). The anti-enzyme activity was determined in agar medium proteinase and phospholipase. To test for cytotoxicity were used fibroblasts (3T3/NIH) and evaluated by colorimetric assays. The data were submitted to ANOVA and Tukey. The results were: MIC and MFC> 15.6 Sgml for C. albicans; MIC and MFC> 62.5 Sgml for C. parapsilosis, MIC and MFC = 62.5 Sgml for C. famata, MIC and MFC = 125 Sgml for C. glabrata and MIC = 15.6 Sgml for C. lipolytica. The average values of phospholipase and proteinase (Pz) of C. albicans before and after exposure were: 0.6 (± 0.024) and 0.2 (± 0.022) and 0.9 (± 0.074) and 0.3 (± 0.04). These results were not statistically significant for proteinase (p = 0.69) but significant for phospholipase (p = 0.01), and the concentration of 15.6 Sgml the most effective. There were no statistical differences between the groups and the control on the cytotoxicity (p = 0.32). It was found that the derivatives are promising pirazolínicos antifungal agents, either by killing the yeasts or inhibition of the enzyme activity, and its low cytotoxicity